Evaluation of cAMS for ¹⁴C Microtracer ADME Studies: Opportunities to Change the Current Drug Development Paradigm

Frédéric Lozac'h1 Novartis Pharma AG, Novartis Institutes for Biomedical Research, PK Sciences, Fabrikstrasse 14, CH-4002Basel, SwitzerlandCorrespondence[email protected]

Simon Fahrni2 Ionplus AG, Dietikon, Switzerland

Daniele De Maria3 Eidgenössische Technische Hochschule Zürich, Department Physik, Zürich, Switzerland

Caroline Welte3 Eidgenössische Technische Hochschule Zürich, Department Physik, Zürich, Switzerland

Joël Bourquin2 Ionplus AG, Dietikon, Switzerland

Hans-Arno Synal3 Eidgenössische Technische Hochschule Zürich, Department Physik, Zürich, Switzerland

David Pearson1 Novartis Pharma AG, Novartis Institutes for Biomedical Research, PK Sciences, Fabrikstrasse 14, CH-4002Basel, Switzerland

Markus Walles1 Novartis Pharma AG, Novartis Institutes for Biomedical Research, PK Sciences, Fabrikstrasse 14, CH-4002Basel, Switzerland

Gian Camenisch1 Novartis Pharma AG, Novartis Institutes for Biomedical Research, PK Sciences, Fabrikstrasse 14, CH-4002Basel, Switzerland

show all

Evaluation of cAMS for ¹⁴C Microtracer ADME Studies: Opportunities to Change the Current Drug Development Paradigm

Supplementary data to

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Evaluation of cAMS for 14C Microtracer ADME Studies: Opportunities to Change the Current Drug Development Paradigm

Supplementary data to

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Evaluation of cAMS for ¹⁴C Microtracer ADME Studies: Opportunities to Change the Current Drug Development Paradigm